Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer.

BACKGROUND The prognostic value of CA19-9 in patients with pancreatic cancer (PC) treated with neoadjuvant therapy has not been well described. METHODS Pre-treatment CA19-9 levels (with concomitant normal bilirubin level) in patients with localized PC were categorized as normal (≤35), low (36-200), moderate (201-1000), or high (>1000). Post-treatment CA19-9 was measured after neoadjuvant therapy, prior to surgery. RESULTS Pre-treatment CA19-9 levels were evaluable in 235 patients, levels were normal in 60 (25%) patients, low in 78 (33%) patients, moderate in 69 (29%) and high in 28 (12%). After neoadjuvant therapy, post-treatment CA19-9 normalized (≤ 35) in 40 (51%) of the patients in the low group, 14 (21%) of the moderate and 5 (19%) of the high group (P < 0.001). Of the 235 patients, 168 (71%) completed all intended therapy including a pancreatectomy; 44 (73%), 62 (79%), 46 (67%) and 16 (57%) of the normal, low, moderate and high groups (P = 0.10). Among these 168 patients, the median overall survival was 38.4, 43.6, 44.7, 27.2 and 26.4 months for normal, low, moderate and high CA19-9 groups (log rank P = 0.72). Among resected patients, an elevated pre-treatment CA19-9 was of little prognostic value; instead, it was the CA19-9 response to neoadjuvant therapy that was prognostic [hazard ratio (HR): 1.80, P = 0.02]. CONCLUSIONS Among patients who completed neoadjuvant therapy and surgery, pre-treatment CA19-9 obtained at the time of diagnosis was not predictive of overall survival, but normalization of post-treatment CA19-9 in response to neoadjuvant therapy was highly prognostic.

[1]  H. Zeh,et al.  Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma , 2014, Annals of Surgical Oncology.

[2]  T. Wilt,et al.  Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. , 2014, Journal of the National Cancer Institute.

[3]  Jeffrey E. Lee,et al.  Radiographic Tumor–Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer , 2014, Journal of Gastrointestinal Surgery.

[4]  J. Cameron,et al.  Institutional Experience With Solid Pseudopapillary Neoplasms: Focus on Computed Tomography, Magnetic Resonance Imaging, Conventional Ultrasound, Endoscopic Ultrasound, and Predictors of Aggressive Histology , 2013, Journal of computer assisted tomography.

[5]  Douglas B. Evans,et al.  Critical steps for pancreaticoduodenectomy in the setting of pancreatic adenocarcinoma , 2013, Journal of surgical oncology.

[6]  J. Werner,et al.  CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy , 2013, Annals of Surgical Oncology.

[7]  Douglas B. Evans,et al.  Current staging systems for pancreatic cancer. , 2012, Cancer journal.

[8]  A. Deshpande,et al.  Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. , 2012, Archives of surgery.

[9]  Bond-Smith Giles,et al.  Only women with symptoms need to have their breast implants removed, says government , 2012 .

[10]  N. D. Merrett,et al.  The prognostic and predictive value of serum CA19.9 in pancreatic cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Choti,et al.  Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. , 2012, Journal of the American College of Surgeons.

[12]  Laura H. Tang,et al.  Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades , 2011, Annals of Surgical Oncology.

[13]  Jeffrey E. Lee,et al.  Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation , 2010, Annals of Surgical Oncology.

[14]  E. Nakakura,et al.  Pancreatic Adenocarcinoma , 2019 .

[15]  M. Farnell,et al.  Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma , 2009, Journal of Gastrointestinal Surgery.

[16]  C. Bassi,et al.  Resectable Pancreatic Cancer: Who Really Benefits From Resection? , 2009, Annals of Surgical Oncology.

[17]  M. Reni,et al.  Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma , 2009, Cancer.

[18]  K. Lillemoe,et al.  Very High Serum CA 19-9 Levels: A Contraindication to Pancreaticoduodenectomy? , 2009, Journal of Gastrointestinal Surgery.

[19]  K. Lillemoe,et al.  Surgical Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.

[20]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Talamonti,et al.  Exocrine and Endocrine Pancreas , 2009 .

[22]  Derrick Wong,et al.  Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy , 2008, Pancreas.

[23]  Jeffrey E. Lee,et al.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. M. Lloyd,et al.  Elevation of Carbohydrate Antigen 19.9 in Benign Hepatobiliary Conditions and Its Correlation with Serum Bilirubin Concentration , 2008, Digestive Diseases and Sciences.

[26]  W. Scheithauer,et al.  CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. , 2008, The Lancet. Oncology.

[27]  J. Drebin.  National Failure to Operate on Early Stage Pancreatic Cancer , 2008 .

[28]  Michael A. Choti,et al.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience , 2006, Journal of Gastrointestinal Surgery.

[29]  U. Halm.  Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Norman,et al.  CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials , 2005, British Journal of Cancer.

[31]  G. Shakhar,et al.  Potential Prophylactic Measures Against Postoperative Immunosuppression: Could They Reduce Recurrence Rates in Oncological Patients? , 2003, Annals of Surgical Oncology.

[32]  R. Edwards,et al.  Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[33]  M. Meurisse,et al.  Cancer in transplant recipients. , 2000, Transplantation proceedings.

[34]  C. Sietses,et al.  Immunological consequences of laparoscopic surgery, speculations on the cause and clinical implications , 1999, Langenbeck's Archives of Surgery.

[35]  T. Ørntoft,et al.  Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. , 1999, Clinical chemistry.

[36]  I. Penn.  The effect of immunosuppression on pre-existing cancers. , 1993, Transplantation.

[37]  J. Sanabria,et al.  Proposed classification of complications of surgery with examples of utility in cholecystectomy. , 1992, Surgery.

[38]  M. Tempero,et al.  Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. , 1987, Cancer research.

[39]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.